Panbela Competitors

Delisted . USA . 
Stock . Panbela Therapeutics
PBLADelisted Stock  USD 2.06  0.11  5.07%   
Panbela Therapeutics competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Revelation Biosciences, Altamira Therapeutics, and Palisade Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Panbela Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Panbela Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Panbela Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.062.062.06
Details
Intrinsic
Valuation
LowRealHigh
1.961.962.27
Details

Panbela Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Panbela Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Panbela and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Panbela Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
VRAX
+ 0.94
NAVB
PALI
+ 0.89
SONN
PALI
+ 0.85
ZVSA
CYTO
+ 0.84
ZVSA
CYTO
+ 0.81
NAVB
SONN
+ 0.8
ZVSA
  
High negative correlations   
UNCY
- 0.81
ZVSA
UNCY
- 0.78
CYTO
UNCY
- 0.75
PALI
UNCY
- 0.65
SONN
UNCY
- 0.53
NAVB
UNCY
- 0.49
VRAX

Risk-Adjusted Indicators

There is a big difference between Panbela Stock performing well and Panbela Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Panbela Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ZVSA  4.10 (0.85) 0.00  0.52  0.00 
 0.00 
 7.57 
(9.60)
 78.93 
SONN  4.71 (0.91) 0.00  1.57  0.00 
 0.00 
 12.31 
(9.79)
 37.58 
REVB  3.68 (0.80) 0.00 (0.28) 0.00 
 0.00 
 8.97 
(7.83)
 34.52 
NAVB  6.04 (1.19) 0.00 (1.62) 0.00 
 0.00 
 12.50 
(12.50)
 40.40 
CYTO  3.49 (1.07) 0.00 (12.97) 0.00 
 0.00 
 6.98 
(10.87)
 22.81 
PALI  3.48 (0.33) 0.00  0.54  0.00 
 0.00 
 5.97 
(8.55)
 24.25 
VRAX  5.73 (0.83) 0.00  2.15  0.00 
 0.00 
 9.65 
(12.90)
 61.28 
QNRX  6.20  0.56  0.05 (0.76) 6.79 
(8.68)
 17.65 
(9.68)
 74.46 
UNCY  4.11  0.62  0.12  0.47  4.32 
(5.22)
 9.76 
(7.41)
 29.22 
CDIO  6.38 (0.61) 0.00  0.00  0.00 
 0.00 
 14.81 
(13.16)
 57.04 
All Fundamental Data

Panbela Therapeutics Competitive Analysis

The better you understand Panbela Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Panbela Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Panbela Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PBLA ZVSA SONN REVB NAVB CYTO PALI VRAX QNRX UNCY
 5.07 
 2.06 
Panbela
 3.60 
 1.07 
ZyVersa
 0.72 
 2.77 
Sonnet
 1.35 
 0.75 
Revelation
 9.45 
 0.1 
Navidea
 2.33 
 0.42 
Altamira
 0.83 
 2.42 
Palisade
 4.27 
 2.02 
Virax
 1.69 
 0.60 
Quoin
 7.27 
 0.59 
Unicycive
Market Volatility
(90 Days Market Risk)
Very steady
Abnormally volatile
Somewhat reliable
Very risky
Very steady
Out of control
Relatively risky
Extremely Dangerous
Out of control
Dangerous
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Very High
Very High
Dangerous
Below Average
Very High
Low
About Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Not Available
Not Available
Strong Buy
Strong Sell
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
0.56
N/A
1.1
0.68
0.22
0.77
2.59
0.04
0.96
4.43
Net Asset
4.98 M
22.11 M
5.43 M
12.21 M
4.37 M
7.69 M
14.05 M
5.48 M
12.17 M
14.19 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(34.76 M)
(107.74 M)
(18.72 M)
(95.21 K)
(14.05 M)
(1.35 M)
(12.28 M)
(6.61 M)
(9.27 M)
(30.18 M)
Current Valuation
8.64 M
(620.73 K)
(1.08 M)
9.41 M
3.5 M
1.95 M
(3.98 M)
1.87 M
(7.28 M)
29.71 M
Price To Book
3.22
0.36
0.89
1.19
8.16
0.25
0.56
1.01
0.56
2.2
Operating Margin
N/A
N/A
-219.69
N/A
N/A
N/A
N/A
-42.54
N/A
N/A
Retained Earnings
(91.09 M)
(103.22 M)
(110.24 M)
(25.47 M)
(388 M)
(18.05 M)
(121.51 M)
(18.53 M)
(46.2 M)
(64.54 M)
Current Asset
N/A
N/A
N/A
N/A
12.58 M
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.83
0.64
1.05
0.15
1.5
2.44
1.33
1.93
1.89
2.29
Number Of Employees
6
7
12
9
11
10
9
17
4
14
Shares Outstanding
3.48 M
2.34 M
837.66 K
4.29 M
100.08 M
3.78 M
1.33 M
4.34 M
5.05 M
103.8 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(15.28 M)
(8.72 M)
(21.34 M)
(7.29 M)
(8.99 M)
(11.51 M)
(11.13 M)
(6.25 M)
(7.86 M)
(18.28 M)
Total Debt
6.84 M
8.66 K
203.91 K
5.56 M
2.43 M
99.66 K
369 K
224.3 K
3.52 K
811 K
Return On Equity
-7.98
-1.52
-2.65
-2.7
-11.0
-3.69
-1.1
-0.96
-1.0
-1.22
Z Score
-49.78
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-1.92
-0.25
-0.97
-0.51
-1.22
-0.57
-0.59
-0.5
-0.36
-0.53
Number Of Shares Shorted
106.97 K
45.48 K
66.23 K
41.24 K
2.69 M
31.09 K
43.11 K
446.54 K
478.43 K
1.05 M
Book Value Per Share
-16.57
27.33
4.01
0.62
-0.011
2.37
18.3
2.09
5.74
-0.11
Current Liabilities
N/A
N/A
N/A
N/A
6.18 M
N/A
N/A
N/A
N/A
N/A
Total Asset
4.98 M
22.11 M
5.43 M
12.21 M
4.37 M
7.69 M
14.05 M
5.48 M
12.17 M
14.19 M
Short Ratio
0.07
0.19
0.03
0.69
0.52
1.08
0.29
0.11
0.2
0.74
Target Price
410.0
20.0
240.0
12.75
5.0
4.5
30.33
20.0
4.5
5.5
Debt To Equity
N/A
N/A
0.36
0.009
1.2
0.045
0.23
N/A
0.47
0.023
Shares Owned By Institutions
0.59
4.47
0.61
2.31
1.5
3.13
3.57
5.37
5.88
38.2
Market Capitalization
3.93 M
2.51 M
2.32 M
3.21 M
8.04 M
1.59 M
3.7 M
8.77 M
3.03 M
61.25 M
Price To Earning
N/A
N/A
N/A
8.69
0.53
N/A
0.16
N/A
N/A
N/A
Price To Sales
N/A
N/A
41.52
2.88
84.14
0.64
14.03
56.07
N/A
62.82
Net Income
(34.93 M)
(98.3 M)
(18.83 M)
(120.25 K)
(15.18 M)
(3.87 M)
(12.3 M)
(6.74 M)
(8.69 M)
(30.54 M)
Earnings Per Share
-157.02
491.97
-0.96
-17.53
-0.39
1.82
-13.26
-2.61
-3.66
-0.46
Shares Owned By Insiders
N/A
0.61
4.22
0.12
35.43
0.52
1.88
7.06
2.44
6.73
Revenue
N/A
N/A
147.81 K
N/A
65.65 K
N/A
250 K
156.42 K
N/A
675 K
Working Capital
(6.06 M)
(6.84 M)
(786.37 K)
6.58 M
(6.74 M)
334.24 K
10.74 M
4.21 M
7.7 M
(4.13 M)
Ten Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
2.53 M
N/A
5.22 M
3.48 M
328.01 K
984.19 K
5 M
21.76 K
2.69 M
10.57 M
Cash Per Share
0.12
N/A
1.21
0.15
0.01
1.29
0.23
N/A
0.56
0.7
Gross Profit
N/A
N/A
(21.09 M)
90.91 M
(119.3 K)
(2.18 M)
N/A
(1.36 K)
N/A
N/A
Day Typical Price
2.08
1.08
2.74
0.75
0.1
0.43
2.44
2.05
0.6
0.58
Accumulation Distribution
0.0691
0.0708
0.0877
0.0263
0.11
0.0667
0.0595
0.0922
0.0328
0.0678
Market Facilitation Index
0.15
0.08
0.25
0.02
0.012
0.03
0.15
0.2
0.02
0.04
Daily Balance Of Power
(0.73)
(0.50)
(0.08)
0.5
(0.87)
(0.33)
0.1333
(0.45)
0.5
1.0
Period Momentum Indicator
(0.11)
(0.04)
(0.02)
0.01
(0.01)
(0.01)
0.02
(0.09)
0.01
0.04
Rate Of Daily Change
0.95
0.96
0.99
1.01
0.91
0.98
1.01
0.96
1.02
1.07
Day Median Price
2.09
1.09
2.73
0.75
0.1
0.44
2.45
2.07
0.6
0.57
Price Action Indicator
(0.09)
(0.04)
0.035
0.005
(0.01)
(0.02)
(0.01)
(0.1)
0.005
0.04
Relative Strength Index
28.29
31.61
32.01
42.05
38.13
33.89
38.78
42.95
45.5
63.99
Coefficient Of Variation
(506.98)
(745.30)
(695.44)
(1,036)
(762.99)
(444.39)
(1,169)
(1,046)
2161.45
634.78
Mean Deviation
7.11
4.1
4.71
3.68
6.04
3.49
3.48
5.73
6.2
4.11
Jensen Alpha
(2.51)
(0.85)
(0.91)
(0.80)
(1.19)
(1.07)
(0.33)
(0.83)
0.5624
0.6232
Total Risk Alpha
(4.10)
(2.40)
(2.06)
(1.47)
(2.42)
(1.80)
(1.19)
(2.33)
(1.20)
(0.01)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0486
0.1218
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
56.44
34.92
Standard Deviation
11.52
8.19
6.79
5.75
8.36
4.68
4.86
9.15
10.71
5.39
Kurtosis
8.2
15.64
2.06
7.68
0.7251
0.7925
3.32
14.11
13.2
1.21
Potential Upside
10.7
7.57
12.31
8.97
12.5
6.98
5.97
9.65
17.65
9.76
Treynor Ratio
(1.21)
0.5241
1.57
(0.28)
(1.62)
(12.97)
0.5362
2.15
(0.76)
0.4667
Maximum Drawdown
88.58
78.93
37.58
34.52
40.4
22.81
24.25
61.28
74.46
29.22
Variance
132.71
67.13
46.16
33.02
69.93
21.93
23.63
83.7
114.76
29.1
Market Risk Adjusted Performance
(1.20)
0.5341
1.58
(0.27)
(1.61)
(12.96)
0.5462
2.16
(0.75)
0.4767
Risk Adjusted Performance
(0.14)
(0.09)
(0.10)
(0.07)
(0.09)
(0.16)
(0.06)
(0.06)
0.0447
0.129
Skewness
(1.07)
0.3839
0.4998
1.79
0.2409
(0.37)
0.5032
2.72
2.59
0.489
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.79
4.32
Information Ratio
(0.21)
(0.15)
(0.16)
(0.12)
(0.15)
(0.25)
(0.11)
(0.11)
0.0341
0.1334
Value At Risk
(17.30)
(9.60)
(9.79)
(7.83)
(12.50)
(10.87)
(8.55)
(12.90)
(9.68)
(7.41)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(8.68)
(5.22)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7.51
5.91
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
46.05
18.64

Panbela Therapeutics Competition Performance Charts

Five steps to successful analysis of Panbela Therapeutics Competition

Panbela Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Panbela Therapeutics in relation to its competition. Panbela Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Panbela Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Panbela Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Panbela Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Panbela Therapeutics position

In addition to having Panbela Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Global Macro ETFs Thematic Idea Now

Global Macro ETFs
Global Macro ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Global Macro ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Global Macro ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Panbela Stock

If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY